Journals / Archives of Rheumatology / 2021 / Cilt: 36 - Sayı: 4

Persistent eosinophilia and associated organ involvement in Thai patients with systemic sclerosis: Data from the Siriraj scleroderma cohort

Pages
527–537
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Compared to non-PH groups, the PH group had a higher prevalence of anti-centromere antibody (ACA), higher baseline percent predicted total lung capacity, and lower baseline C-reactive protein and creatine phosphokinase (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to investigate the prevalence of persistent eosinophilia and associated organ complications in Thai patients with systemic sclerosis (SSc).
📊
Key Findings & Data:Patients and methods: This post-hoc study included 107 adult patients (23 males, 84 females; mean age: 50.4±11.6 years; range, 18 to 79 years) diagnosed with SSc between November 2013 and June 2017.
💡
Conclusion & Impact:Compared to non-PH groups, the PH group had a higher prevalence of anti-centromere antibody (ACA), higher baseline percent predicted total lung capacity, and lower baseline C-reactive protein and creatine phosphokinase (p
🔬Design:Research Article
📍Scope:2013 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: This study aims to investigate the prevalence of persistent eosinophilia and associated organ complications in Thai patients with systemic sclerosis (SSc). Patients and methods: This post-hoc study included 107 adult patients (23 males, 84 females; mean age: 50.4±11.6 years; range, 18 to 79 years) diagnosed with SSc between November 2013 and June 2017. Eosinophilia was defined as an absolute eosinophil count of >500/μL or a percentage count of >7%. Eosinophil levels collected at every visit over one year were categorized as persistently high (PH), persistently low (PL), high-to-low (HL), low-to-high (LH), or variable levels (VL). The study compared variables between PH and non-PH (PL+HL+LH+VL) groups. The patients with baseline eosinophilia were also identified and compared with the non-eosinophilia group. Results: The median disease duration was 3.2 years. Of the patients, 79.4% had diffuse cutaneous SSc and 76.7% had anti-Scl-70 positivity. A total of 11.2%, 66.4%, 1.9%, 8.4%, and 12.1% of the patients were categorized into the PH, PL, HL, LH, and VL groups, respectively. Compared to non-PH groups, the PH group had a higher prevalence of anti-centromere antibody (ACA), higher baseline percent predicted total lung capacity, and lower baseline C-reactive protein and creatine phosphokinase (p

🔖

Cite This Article

Punjasamanvong, S., Muangchan, C. (2022). Persistent eosinophilia and associated organ involvement in Thai patients with systemic sclerosis: Data from the Siriraj scleroderma cohort. Archives of Rheumatology, Cilt: 36 - Sayı: 4, 527–537. https://ajindex.com/articles/448016

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Feghali-Bostwick C, Varga J. Introduction: The etiopathogenesis of systemic sclerosis-an integrated overview. In: Varga J, Denton CP, Wigley FM, Allanore Y, Kuwana M, editors. Scleroderma: from pathogenesis to comprehensive management. 2nd ed. New York: Springer; 2017. p. 133-9
  2. Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE. Pathogenesis of systemic sclerosis. Front Immunol 2015;6:272
  3. Akter T, Silver RM, Bogatkevich GS. Recent advances in understanding the pathogenesis of sclerodermainterstitial lung disease. Curr Rheumatol Rep 2014;16:411
  4. Gieseck RL 3rd, Wilson MS, Wynn TA. Type 2 immunity in tissue repair and fibrosis. Nat Rev Immunol 2018;18:62-76
  5. Rosenberg HF, Dyer KD, Foster PS. Eosinophils: Changing perspectives in health and disease. Nat Rev Immunol 2013;13:9-22
  6. Kato Y, Fujisawa T, Nishimori H, Katsumata H, Atsuta J, Iguchi K, et al. Leukotriene D4 induces production of transforming growth factor-beta1 by eosinophils. Int Arch Allergy Immunol 2005;137 Suppl 1:17-20
  7. Gu YS, Kong J, Cheema GS, Keen CL, Wick G, Gershwin ME. The immunobiology of systemic sclerosis. Semin Arthritis Rheum 2008;38:132-60
  8. Roufosse F. L4. Eosinophils: How they contribute to endothelial damage and dysfunction. Presse Med 2013;42:503-7
  9. Liapis H, Ho AK, Brown D, Mindel G, Gleich G. Thrombotic microangiopathy associated with the hypereosinophilic syndrome. Kidney Int 2005;67:1806-11
  10. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002;165:1581-6
  11. Hesselstrand R, Wildt M, Bozovic G, AnderssonSjöland A, Andréasson K, Scheja A, et al. Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis. Respir Med 2013;107:1079-86
  12. De Santis M, Bosello SL, Peluso G, Pinnelli M, Alivernini S, Zizzo G, et al. Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease. Clin Respir J 2012;6:9-17
  13. Mackintosh JA, Stainer A, Barnett JL, Renzoni EA. Systemic sclerosis associated interstitial lung disease: A comprehensive overview. Semin Respir Crit Care Med 2019;40:208-26
  14. Ando K, Nakashita T, Kaneko N, Takahashi K, Motojima S. Associations between peripheral blood eosinophil counts in patients with systemic sclerosis and disease severity. Springer